Preconditioning Absolute Lymphocyte Count and Transplantation Outcomes in Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation Recipients with Reduced-Intensity Conditioning and Antithymocyte Globulin Treatment
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment option for several types of hematologic malignancies, including high-risk or relapsed acute leukemia and myelodysplastic syndrome (MDS), and some benign hematological diseases, such as severe aplastic anemia. Despite the significant progress in transplant technology and patient care that has been made since the 1960s, there are still obstacles that hinder achieving successful outcomes after allo-HSCT.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Go-Un Woo, Junshik Hong, Hyangseon Kim, Ja Min Byun, Youngil Koh, Dong-Yeop Shin, Inho Kim, Sung-Soo Yoon Source Type: research
More News: Acute Leukemia | Anemia | Aplastic Anemia | Biology | Cancer & Oncology | Hematology | Leukemia | Myelodysplastic Syndrome | Stem Cell Therapy | Stem Cells | Transplants